Valuation: Beam Therapeutics Inc.

Market Cap 2.09B 1.9B 1.75B 1.59B 2.99B 193B 3.14B 21.32B 8.47B 106B 7.83B 7.67B 331B P/E 2026 *
-4.52x
P/E 2027 * -4.03x
Enterprise Value 1.2B 1.09B 1B 914M 1.71B 111B 1.8B 12.23B 4.86B 60.54B 4.49B 4.4B 190B EV / Sales 2026 *
31.1x
EV / Sales 2027 * 64.6x
Free-Float
98.8%
Yield 2026 *
-
Yield 2027 * -
1 day-0.19%
1 week-13.03%
Current month-23.25%
1 month-13.60%
3 months-28.10%
6 months-20.62%
Current year-24.60%
1 week 20.44
Extreme 20.44
22.7
1 month 20.44
Extreme 20.44
29.76
Current year 20.44
Extreme 20.44
38.26
1 year 20.39
Extreme 20.39
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
90.44
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2017
Director of Finance/CFO 48 19/12/2024
President 57 24/01/2020
Director TitleAgeSince
Director/Board Member 48 01/01/2017
Director/Board Member 75 01/05/2018
Director/Board Member 56 10/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/26 Exercice

Chief Executive Officer

75,000 0.0726%
01/10/26 Sell

Controller/Auditor

-187 0.0002%
24/09/26 Don

Chairperson

-123,407 0.1195%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-13.03%-0.38%-23.92% 2.09B
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-2.19%-6.02%+10.50%+109.19% 45.66B
-1.89%-9.33%+13.03%+20.04% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.11%-8.59%+128.56%+655.74% 34.48B
-0.80%-1.73%+75.29%+56.47% 32.5B
-2.17%+19.70%-30.57%+469.42% 31.69B
Average -1.26%-1.88%+29.82%+156.89% 40B
Weighted average by Cap. -1.48%-1.34%+31.46%+150.51%

Financials

2026 *2027 *
Net sales 38.53M 35.09M 32.34M 29.41M 55.18M 3.57B 58M 394M 156M 1.95B 145M 142M 6.12B 26.39M 24.03M 22.15M 20.14M 37.79M 2.44B 39.72M 270M 107M 1.33B 99M 96.92M 4.19B
Net income -481M -438M -404M -367M -689M -44.54B -724M -4.91B -1.95B -24.33B -1.8B -1.77B -76.35B -561M -511M -471M -428M -804M -51.96B -845M -5.73B -2.28B -28.38B -2.11B -2.06B -89.06B
Net Debt -890M -811M -747M -680M -1.27B -82.43B -1.34B -9.09B -3.61B -45.02B -3.34B -3.27B -141B -382M -348M -321M -292M -548M -35.41B -576M -3.91B -1.55B -19.34B -1.43B -1.4B -60.69B
Projected Income Statement - Annual - Beam Therapeutics Inc.
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
557
Date Price Change Volume
20/11/26 $20.93 -0.05% 3,881,798
19/11/26 $20.94 -0.33% 4,214,361
18/11/26 $21.01 +1.74% 4,867,440
17/11/26 $20.65 -1.38% 4,127,713
16/11/26 $20.94 -8.28% 3,332,610
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Beam Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
20.93USD
Average target price
49.85USD
Spread / Average Target
+138.16%
  1. Stock Market
  2. Stocks
  3. BEAM Stock